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Quick Reference Guide
1. General management
•  Chronic non-cancer pain (CNCP) is defined as 
pain lasting for >90 days and beyond the expected 
time for tissue healing.
• CNCP is often associated with psychological 
comorbidities (anxiety and depression) and limitation of physical 
function.
• Management of CNCP requires a multimodal, multidisciplinary 
approach to address:




• Patients should be referred to specialist practitioners for interven-
tions when appropriate, and thereafter referred back to the general 
practitioner for continued care.
• Communication between the patient’s healthcare team is 
mandatory to establish roles and expectations for continuity of 
care and safe use of opioids. 
• Patients should identify with one doctor (usually the general 
practitioner) who accepts primary responsibility for their overall 
medical care and who should coordinate communication and 
consultation among clinicians. 
• To help ensure correct use of medication and to reduce prescription 
fraud, all opioids (and preferably all other medications) for a 
particular patient should be dispensed through a single designated 
pharmacy.
• Chronic opioid therapy (COT) is defined as regular use of strong 
opioids for at least 3 months.
2. Indications for opioids
• Opioids may be appropriate in carefully selected patients with 
moderate to severe pain, which:
• significantly and adversely affects quality of life, or
• has not responded to non-pharmacological and non-opioid 
pharmacological therapies.
• Opioids are not appropriate as the primary medication of choice 
for pain disorders with strong psychosocial contributing factors.
3. Before initiating COT 
• Establish a diagnosis and the cause of the pain.
• Estimate the pain intensity and functional impairment.
• Risk stratify the patient in terms of potential benefits and harms of 
opioid therapy to assess their suitability for COT.
3.1 Patient assessment and diagnosis
• Patient’s pain disorder
• Pain intensity
• Functional impairment (impact of pain on work, school/studying, 
home and leisure activities)
• General medical condition
• Sleeping pattern
• Psychosocial history (living arrangements, family/social support, 
family obligations, work status)
• Psychiatric status
• Substance use history
• Other medications
Assessment tools to evaluate patients for COT  
(Appendix 1 and 2)
Tool Purpose When to complete
BPI To evaluate physical and 
psychosocial components of pain
All visits
ORT To evaluate risk of opioid abuse Initial visit
COT = chronic opioid therapy; BPI = Brief Pain Inventory; ORT = Opioid Risk Tool.
The full version of this guideline is available online. Use the QR code to access.
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3.2 Explain treatment options and address expectations
• Total pain relief is rarely achieved.
• Goals of therapy are pain reduction and functional improvement:
• Clinically meaningful improvement is at least 30% reduction in 
pain (or ≥2 points on a 0 - 10 numerical rating scale) and/or 30% 
improvement in function.
• Caution patients against unrealistic expectations.
• Potential benefits, adverse effects, complications and risks of COT.
• Alternatives to COT.
• Consider asking the patient to sign an opioid agreement (Appendix 3).
• Initial course of COT is viewed as a short-term trial, which will be 
continued if response is satisfactory.
• Positive clinical response to COT may take a few days to become 
apparent.
Detailed notes of all assessments, discussions and treatment decisions 
should be maintained at all visits.
4. Choice of opioid
• Opioid analgesics for CNCP may be administered orally or 
transdermally.
• When choosing an appropriate opioid, consider health status, 
pain severity, previous exposure to opioids, attainment of 
therapeutic goals and predicted or observed harms, concomitant 
medications.
• Use immediate release (IR) oral opioids to initiate therapy and 
titrate to an effective dose.
• Once pain control is stable, if possible, switch to long-acting 
(controlled release (CR); extended release (ER), sustained release 
(SR)) oral opioid or transdermal opioid patch.
5. Initiation and titration of COT
• Start with a low dose: ≤10 mg/day oral morphine equivalents. 
• Reassess dose after 72 h (clinical improvement and tolerability).
• Dose may be slowly increased by not more than 10 mg morphine 
equivalents per day over 4 - 6 weeks.
• Maximum daily dose should preferably not exceed 90  mg oral 
morphine equivalents.
• If repeated dose escalations are required, consider:
• increase in the intensity of the underlying pain condition 
(disease progression)
• development of an additional painful condition
• opioid tolerance
• opioid-induced hyperalgesia
• drug abuse (e.g. recreational use).
Step-wise approach to opioid selection
Mild-to-moderate pain Severe pain
First-line Codeine or tramadol Morphine, high-dose oxycodone, hydromorphone, or buprenorphine
Second-line Morphine, low-dose oxycodone, dihydrocodeine, 
hydromorphone or buprenorphine
Fentanyl
Oral opioids: Suggested initial dose and titration*,†
Opioid Initial dose
Min. time interval for 
increase (days) Suggested dose increase
Min. daily dose before 
converting IR to CR
Codeine (alone/
in combination with 
paracetamol/ASA)
15 - 30 mg 4-hourly as 
required
7 15 - 30 mg/day,  
max. 600 mg/day‡ 
100 mg 
Tramadol (37.5 mg) + 
paracetamol (325 mg)
1 tablet 4 - 6-hourly 7 1 - 2 tablets 4 - 6-hourly as 
needed, max. 8 tablets/day
3 tablets
Tramadol 50 mg 4 - 6-hourly Max. dose: 400 mg/day NA
SR tramadol 100 mg 12-hourly 2 Max. dose: 400 mg/day NA
IR morphine 5 - 10 mg 4-hourly as 
needed, max. 40 mg/
day
7 5 - 10 mg/day 20 - 30 mg
CR morphine 10 - 30 mg 12-hourly Min. 2, recommended: 14 5 - 10 mg/day NA




CR oxycodone 10 - 20 mg 12-hourly, 
max. 40 mg/day
Min. 2, recommended: 14 10 mg/day NA
ER hydromorphone 4 mg daily, max. 16 mg/
day
Min. 2, recommended: 14 2 - 4 mg/day NA
Dihydrocodeine 30 mg 6-hourly Min. 2, recommended: 7 Increase to 30 mg every 4 h, 
max. 240 mg/day
NA
IR = immediate release; CR = controlled release; ASA = acetylsalicylic acid; ER = extended release; SR = sustained release.
*Modified from the Canadian National Opioid Use Guideline Group (2010).[4]
† Due to a genetic polymorphism that influences the response to opioid analgesics, there is inter-individual variation in the doses required for adequate analgesia. Some patients will require 
considerably higher opioid doses than others.
‡Paracetamol dose should not exceed 3 g/day.
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6.  Consider switching to another 
opioid if: 
• Analgesia is inadequate despite dose escalation
• Adverse effects are intolerable
• Stable pain control is achieved on IR opioid and it is appropriate to 
switch to a long-acting formulation or transdermal opioid patch.
7. Breakthrough pain
• Consider as-needed IR opioid for rescue analgesia.
• If continuous rescue doses are required, up-titrate maintenance 
analgesic dose by adding the extra dose per day required for 
breakthrough pain.
8. Long-term opioid prescribing
When a trial of opioid has been successful, treatment may be 
continued until:
• the underlying painful condition resolves
• the patient receives a definitive pain relieving intervention (e.g. 
joint replacement)
• the patient no longer derives benefit from opioid treatment
• the patient develops intolerable side-effects; or
• there is evidence of addiction, tolerance, dependence or 
opioid-induced hyperalgesia. It should be noted that patients 
who are suffering with severe pain rarely become addicted 
to opioids. They may require increasing doses of opioids as a 
result of opioid tolerance and this must be differentiated from 
addiction.
9. Discontinuing opioids
• Reduce dose slowly by approximately 10% per day or per week.
• Dose should be tapered more slowly in patients who are anxious 
about discontinuing COT and in those who are suspected of being 
physically dependent on opioids.
• When one-third of the original dose is reached, reduce the rate of 
tapering to one-half or less of the initial rate. 
• If the patient experiences withdrawal symptoms or an increase in 
pain during tapering, discontinue dose reduction and consider 
increasing the current dose.
Equianalgesic doses for conversion from one oral opioid to another*,†
Opioid Equivalence to 30 mg morphine (mg)
Conversion to/from oral morphine equivalent – multiply by
To From 
Morphine 30 1 1
Codeine 200 0.15 6.67
Oxycodone 20 1.5 0.67
Hydromorphone 6 5 0.2
Dihydrocodeine 180 0.16 6
Tramadol ~1:10‡
*Adapted from the Canadian National Opioid Use Guideline Group (2010).[4]† If converting from opioids other than morphine, calculate the equipotent morphine dose for the current analgesic and use this dose to convert to the new opioid. The new opioid should be 
initiated at 50% of the calculated equianalgesic dose. ‡ Morphine dose equivalence not established, but approximates to 1:10 of morphine to tramadol.
Approximate equipotent doses for conversion from oral morphine to transdermal opioids
Oral morphine to transdermal fentanyl*,†
Oral morphine equivalent (mg/24 h) 60 - 134 135 - 179 180 - 224 225 - 269 270 - 314 315 - 359 360 - 404
Transdermal fentanyl (μg/h)‡ 25 37 50 62 75 87 100
Oral morphine to transdermal buprenorphine§,¶
Oral morphine equivalent (mg/24 h) 10 15 30 60 90 120 180 240
Transdermal buprenorphine (μg/h) 5 10 20 35 52.5 70 105 140
*Adapted from the Canadian National Opioid Use Guideline Group (2010).[4]
† Conversion rate is 150:1,[6] e.g. 120 mg morphine over 24 h: 120 ÷ 150 = 0.8 mg fentanyl; 0.8 × 1 000 = 800 μg fentanyl over 24 h = 33.3 μg /h. Round up or down to appropriate patch. 
‡ Formulations include 12, 25, 50, 75 and 100 μg/h patches, but the 12 μg/h patch is generally used for dose adjustment rather than initiation of fentanyl treatment.
§ Adapted from the British Pain Society (2010).[2]
¶ Conversion rate is 75 - 100:1.[2,6] The conversion rate used here is based on 75:1, e.g. 30 mg morphine over 24 h: 30 ÷ 75 = 0.4 mg buprenorphine; 0.4 × 1 000 = 400 μg buprenorphine over 24 h = 
16.6 μg/h. Round up or down to appropriate patch.
Common opioid-related adverse effects and their management
Adverse effect Management
Nausea/vomiting Anti-emetic therapies (oral or suppository); it is advisable to concurrently prescribe a prophylactic anti-emetic 
for a few days when initiating opioid therapy
Constipation Increase fluid and fibre intake; stool softeners; laxatives
Pruritus Antihistamine
Sedation, clouded mentation Pharmacological therapies are not recommended
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10. Opioid-related adverse effects
Adverse effects are usually manageable and most pronounced when 
initiating or increasing the dose.
10.1 For intolerable adverse effects, consider
• Reducing the opioid dose.
• Switching to another opioid formulation or route of administration.
• Discontinuing the opioid and instituting alternative pain management 
strategies.
11.  Driving and working while on 
opioids
Patients should be advised to avoid driving, working under hazardous 
conditions or working with hazardous machinery if: 
• the condition for which they are being treated has physical 
consequences that might impair their driving ability, concentration 
or coordination
• they feel unfit to drive or work
• they have constant severe pain
• they have not been sleeping
• they have just started opioid treatment
• their dose of opioids has been recently adjusted upwards or 
downwards (as withdrawal may have an impact on capability)
• they have consumed alcohol or other drugs that can produce an 
additive sedative effect.
12.  When to refer to a pain clinician 
or multidisciplinary pain unit
• Unable to make a definite diagnosis of the cause of pain
• Significant comorbidities or other factors that may complicate 
opioid use (e.g. psychiatric comorbidities, severe renal impairment, 
etc.)
• Inadequate response to opioid analgesia, despite titration to 
90 mg/day oral morphine equivalent
• Unmanageable opioid-related side-effects
• Indications of inappropriate drug use.
Clinical features of opioid toxicity and withdrawal
Symptoms 
Toxicity Pinpoint pupils
Sedation (falling asleep during 
conversation or activity)
Slow respiration






Vivid dreams, nightmares or 
hallucinations









Bone and muscle pain
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Patients with chronic non-cancer pain
                  Initial steps
· Comprehensive assessment
· Assessment of risk of misuse
· Screening tests: BPI, ORT
                                   Diagnosis
· X-rays, MRI, CT, neurophysiological studies
· Psychological evaluation (basic)
· Precision diagnostic interventions (optional)
· Consultation/s as needed




· Behavioural interventions (optional)
· Interventional pain management (optional)
· Other alternatives
· Consultation/s as needed
                      Treatment goals
· Decrease pain by 30% and/or increase 
  function by 30%
· Minimal adverse eects
Assess eectiveness of opioid therapy
  Informed decision-making
· Opioid agreement 
· Random evaluations
  including pill counts and 
  urine drug testing
 
 Initial treatment (8 - 12 weeks)
· Stratication of risk
· Understanding opioids
· Initiation with low-dose, short-
  acting opioid therapy
· Titrate
 
          Adherence monitoring
· Prescription drug monitoring
  programmes
· Urine drug testing
· Pill counts
· Behavioural assessment during
  each visit
 
           Side-eects





                    Discontinue
· Persistent or new pain
· Abuse, misuse
· Lack of analgesia




                  Continue
· Analgesia of 30% and/or
  activity increase by 30%
· No misuse, abuse, adverse
  eects, manageable
 






· Wean, discharge, or maintain
 
Algorithm for the initiation and use of COT. Adapted with permission from Manchikanti et al.[5] (COT = chronic opioid therapy; BPI = Brief Pain Inventory; 
ORT = Opioid Risk Tool; MRI = magnetic resonance imaging; CT = computed tomography.)
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Appendix 1. Brief Pain Inventory*
Name: _____________________________________ 7.  What treatments or medications are you receiving for your pain?
Date: _____________________________________
Time: _____________________________________
1.  Throughout our lives, most of us have had pain from time to 
time (such as minor headaches, sprains and toothaches). Have 
you had pain other than these everyday kinds of pain today?
☐ YES                 ☐ NO 8.  In the past 24 h, how much relief have pain treatments or 
medications provided? Please circle the percentage that shows how 
much relief you have received.
2.  On the diagram, shade the area where you feel pain. Put an X on 
the area that hurts the most.
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
No relief Complete relief
9.  Circle the number that describes how, during the past 24 h, pain has 
interfered with your:
A. General activity
0 1 2 3 4 5 6 7 8 9 10
Does not interfere Completely interferes
B. Mood
0 1 2 3 4 5 6 7 8 9 10
3.  Please rate your pain by circling the number that best describes 
your pain at its worst in the past 24 h.
Does not interfere Completely interferes
C. Walking ability
0 1 2 3 4 5 6 7 8 9 10 0 1 2 3 4 5 6 7 8 9 10
No pain Pain as bad as you can imagine Does not interfere Completely interferes
4.  Please rate your pain by circling the number that best describes 
your pain at its least in the past 24 h.
D.  Normal work (includes both work outside the home and 
housework)
0 1 2 3 4 5 6 7 8 9 10 0 1 2 3 4 5 6 7 8 9 10
No pain Pain as bad as you can imagine Does not interfere Completely interferes
5.  Please rate your pain by circling the number that best describes 
your pain on average.
E. Relations with other people
0 1 2 3 4 5 6 7 8 9 10
0 1 2 3 4 5 6 7 8 9 10 Does not interfere Completely interferes
No pain Pain as bad as you can imagine F. Sleep
6.  Please rate your pain by circling the number that tells how much 
pain you have right now.
0 1 2 3 4 5 6 7 8 9 10
Does not interfere Completely interferes
0 1 2 3 4 5 6 7 8 9 10 G. Enjoyment of Life
No pain Pain as bad as you can imagine 0 1 2 3 4 5 6 7 8 9 10
Does not interfere Completely interferes
*Reproduced with permission from Dr Charles S Cleeland (1991).
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Appendix 2. Opioid Risk Tool*
Risk factor Male, score (max. score) Female, score (max. score)
Family history (parents and siblings)
Alcohol abuse _ (3) _ (1)
Illegal drug use _ (3) _ (2)
Prescription drug abuse _ (4) _ (4)
Personal history
Alcohol abuse _ (3) _ (3)
Illegal drug use _ (4) _ (4)
Prescription drug abuse _ (5) _ (5)
Mental health
Diagnosis of ADD, OCD, bipolar disorder or schizophrenia _ (2) _ (2)
Diagnosis of depression _ (1) _ (1)
Other
Age 16 - 45 years _ (1) _ (1)
History of pre-adolescent sexual abuse _ (0) _ (3)
Total score
Total score risk category:
0 - 3 = low risk: 6% chance of developing problematic behaviours
4 - 7 = moderate risk: 28% chance of developing problematic behaviours
≥8 = high risk: >90% chance of developing problematic behaviours
ADD = attention deficit disorder; OCD = obsessive-compulsive disorder.
*Reproduced with permission from Webster LR and Webster RM.[13]
Appendix 3. Sample opioid agreement
I (patient’s name)                                   understand that Dr                                is prescribing opioid medication for me to treat my chronic pain.
The opioid medication that has been prescribed is:                                                                                                                          .
The risks and benefits of this medicine have been explained to me and I understand the following:
• the medicine may have certain side-effects including, but not limited to, drowsiness, dizziness, loss of coordination, constipation, nausea, 
vomiting and itching
• the medication may impair my ability to drive a motor vehicle, operate hazardous machinery or work under hazardous conditions
• alcohol and certain other medications may increase the risk of side-effects while I am taking opioid medication, or may reduce the 
effectiveness of my pain medication
• although the risk is low, addiction to opioid medication can occur; addiction is more likely to occur in people with a personal or family 
history of drug or alcohol abuse and/or addiction
• physical dependence to opioid medication may occur and may result in withdrawal symptoms if the medication is stopped abruptly
• opioid medication may not provide complete pain relief; if the pain or ability to be active does not improve after a reasonable trial of opioid 
medication, the medication may be stopped.
I agree to the following:
1.  Only Dr                                                      will prescribe opioids for me, and I will not seek or accept opioid medications from anyone else. 
2.  I will take my opioid medication exactly as instructed by Dr                            and will not take it in larger doses or more frequently than instructed. 
3.  I will tell Dr                                                    about all other medications I am taking and about any personal/family history of alcohol/drug 
abuse or illegal drug activity. I will not use any other prescribed or over-the-counter medication without discussing it with him/her first.
4.  I will not give my opioid medication to anyone else and I will store it in a safe and secure place and out of the reach of children. 
5.  (Females only) I will tell my doctor immediately if I am planning to become pregnant or if I think that I am or might be pregnant.
6.  My medical practitioner may decide to discontinue my opioid medication if my pain or ability to be active does not improve, or if I do not 
comply with any of the above.
Patient signature:                                                          Date:                                                          Witness:                                                          
